Microcirculation Recruitment Using Albumin 20% and Terlipressin in Septic Patients

• Status: Not yet recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the effect of combining HSA 20% and terlipressin on the microcirculation in patients with septic shock using the following;-

• Microcirculation recruitment by Cytocam-IDF.

• Cardiac output by LiDCOrapid.

• Measuring serum lactate level.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amany Mousa Salama Muhammed
• Treatments: Terlipressin

Criteria

Inclusion Criteria:

• The presence of septic shock meeting all of the following criteria less than 24 hours:-

1. Clinically possible or probable or microbiologically confirmed infection taking into account the definitions of the "International Sepsis Forum (ISF)"

2. Despite adequate volume therapy, vasopressors are required to maintain mean arterial pressure (MAP) ≥ 65 mm Hg.

3. Serum lactate level > 2 mmol/l (18 mg/dl) despite adequate volume therapy.

Exclusion Criteria:

• Patients who failed to achieve target MAP despite adequate resuscitation with fluids and maximum dose of noreadrenaline.

• Acute coronary artery disease or underlying cardiac dysfunction [cardiac index (CI) <2.2 l/min/m 2 ].

• Severe liver disease (Child-Pugh grade C)

• Chronic renal failure.

• Known hypersensitivity to Norepinephrine, terlipressin and human albumin.

• Those having Raynaud's phenomenon, or a vasospastic diathesis and

• Other causes of shock e.g.; hemorrhagic hypovolaemia, cardiogenic shock, anaphylactic shock, neurogenic shock.

• Pregnant patients and lactation.